Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35
Roth Capital analyst Boobalan Pachaiyappan downgrades LB Pharmaceuticals (NASDAQ:LBRX) from Buy to Neutral and lowers the price target from $37 to $35.
Share
Why It Matters
An analyst became less excited about LB Pharmaceuticals and lowered expectations. When experts change their minds, it hints the company might face challenges ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.